

**2022 NCODA International Fall Summit  
Physician and Registered Nurse Sessions CE Information**

October 27 – 29, 2022 | Orlando, FL

Jointly provided by Partners for Advancing Clinical Education (PACE) and NCODA

**Target Audience**

This conference is intended for oncology healthcare providers that include; pharmacists, pharmacy technicians, physicians and nurses who care for patients within oncology.

**Individual CME/CNE Session Educational Objectives**

Upon completion of each session, participants should be able to:

**An Overview of FGFR Inhibitors**

- Evaluate the safety and efficacy of FGFR inhibitors and their current place in treatment
- Discuss appropriate management plans to effectively treat and monitor for adverse events associated with FGFR inhibitors based on treatment guidelines and outcomes from clinical trials

**Unprecedented and Unexpected: Immunotherapy in Early-Stage Rectal Cancer**

- Recognize the toxicities and long-term sequelae from current treatment of early stage rectal cancer
- Summarize the results of the phase II trial by Cercek et al. in early stage rectal cancer patients with MSI-H/dMMR disease

**Resources for Nurses to Improve Compliance and Adherence to Oral Oncolytic Regimens**

- Provide multiple NCODA nursing resources to help with oral chemotherapy compliance and adherence
- Discuss how technology can be used to help improve patient care and outcomes
- Define medication adherence
- Define clinician-patient based interventions to assess and promote patient adherence to medication regimens
- Summarize the patient, clinician, and system factors that contribute to poor medication adherence

**Updates in Treatment of Metastatic Melanoma**

- Review updates in treatment recommendations for adult patients with newly diagnosed Stage IV metastatic melanoma
- Analyze available literature supporting the use of the newly approved LAG-3 inhibitor in metastatic melanoma and discuss its place in therapy
- Compare the safety profile of nivolumab plus relatlimab with nivolumab plus ipilimumab

**Updated Treatment Options in Metastatic Uveal Melanoma**

- Review treatment options for uveal melanoma
- Discuss the role of new treatment options for metastatic uveal melanoma
- Describe the administration and management of toxicities associated with the treatment options for uveal melanoma

### **Thanatology for Oncology Healthcare Professionals**

- Discuss the current state of thanatology education in practice
- Appraise the importance of understanding thanatology to the medically integrated oncology team and how it relates to professional development and burnout
- Evaluate key resources and methods for integrating thanatology education into practice
- Explain methods for integrating thanatology education into their clinical practice setting for students, residents and practitioners

### **How Low Can We Go? Updates in HER2-Low Breast Cancer**

- Review current treatment options for metastatic breast cancer
- Evaluate data from the DESTINY-Breast04 trial and implications in the treatment of metastatic breast cancer
- Identify common side effects associated with HER2 targeted therapy and provide effective management strategies

### **Updates in ITP: From TPO to SYK**

- Discuss the latest international guideline recommendations on the management of adult and pediatric immune thrombocytopenia
- Evaluate recent key clinical trials in the management of ITP
- Summarize patient counseling and monitoring considerations associated with ITP therapies

### **Chemotherapy, Herbals, and Food - How to Identify Potential Interactions**

- Explain what herbal products are and define related terminology
- Identify common dietary supplements
- Identify screening questions to ask your patients
- List the most common food, herbal, and chemotherapy interactions
- Describe how to perform medication reconciliation and provide reliable resources on common herbal products for patients as well as health care professionals

### **Molecular Testing for Non-Small Cell Lung Cancer**

- Explain the information being conveyed in a next generation sequencing report
- Compare and contrast the benefits and limitations between solid tumor and liquid next generation sequencing test
- Use the information in a next generation sequencing report to develop a treatment plan for a patient with NSCLC

### **The Anatomy of Collaborative Practice Agreement**

- Examine the legal ambiguity of collaborative practice agreements with regard to board of pharmacy and institutional regulations
- Review essential components for executing a collaborative practice agreement to manage patients receiving oral oncolytic therapy
- Discuss real world barriers to develop and implement a collaborative practice agreement through application of case presentations

**Faculty and Disclosure of Conflicts of Interest**

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The **faculty** reported the following financial relationships or relationships to products or devices they have with ineligible companies:

<b>Faculty</b>	<b>Relevant Financial Relationships</b>
Benyam Muluneh, PharmD, BCOP, CPP	Consultant/Advisor/Speaker: Servier
Courtney Cavalieri, PharmD, BCOP	Consultant/Advisor/Speaker: Pfizer
Erin Sypolt, PharmD, BCOP	Consultant/Advisor/Speaker: Bayer
Jessie Modlin, PharmD, BCOP	Consultant/Advisor/Speaker: Janssen, BeiGene
Jill Kolesar, PharmD, MS	Other (grant support for clinical trial): ArtemiLife, LOXO@Lilly; Owner: Helix
Maya Leiva, PharmD, BCOP	Consultant/Advisor/Speaker: Amgen, BMS, wellCORNER, Myovant, Cornerstone Specialty Network
Robert Mancini, PharmD, BCOP, FHOPA	Consultant/Advisor/Speaker: Takeda, GSK
All other faculty	Have no relevant financial relationships with ineligible companies to disclose.

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The NCODA planners and others no relevant financial relationship(s) to disclose with ineligible companies.

**Joint Accreditation Statement**



In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and NCODA. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Physician Continuing Education\***

PACE designates this live activity for a maximum of 5 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nursing Continuing Education\***

The maximum number of hours awarded for this Continuing Nursing Education activity is 5 contact hours.

### **\*Individual Session Credits**

- An Overview of FGFR Inhibitors – 0.5 CME credit/CNE contact hour
- Unprecedented and Unexpected: Immunotherapy in Early-Stage Rectal Cancer – 0.5 CME credit/CNE contact hour
- Resources for Nurses to Improve Compliance and Adherence to Oral Oncolytic Regimens – 1.0 CME credit/CNE contact hour
- Updates in Treatment of Metastatic Melanoma – 0.5 CME credit/CNE contact hour
- Updated Treatment Options in Metastatic Uveal Melanoma– 0.5 CME credit/CNE contact hour
- Thanatology for Oncology Healthcare Professionals – 1.0 CME credit/CNE contact hour
- How Low Can We Go? Updates in HER2-Low Breast Cancer – 0.5 CME credit/CNE contact hour
- Updates in ITP: From TPO to SYK – 0.5 CME credit/CNE contact hour
- Chemotherapy, Herbals, and Food - How to Identify Potential Interactions – 1.0 CME credit/CNE contact hour
- Molecular Testing for Non-Small Cell Lung Cancer – 1.0 CME credit/CNE contact hour
- The Anatomy of Collaborative Practice Agreement – 1.0 CME credit/CNE contact hour

### **Disclosure of Unlabeled Use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### **Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

### **Instructions for Credit**

CE Credit for the 2022 NCODA Fall Summit can be claimed through the LecturePanda platform. To register, please visit: <https://www.lecturepanda.com/a/NCODA2022FallSummit>

